Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
TFC heads into its October 16 Q3 earnings report with defensive options positioning that has grown more pronounced since the last note five days ago, even as the stock has recovered slightly from its recent lows.
The put/call ratio has continued climbing. At 0.896, it now sits more than two standard deviations above its 20-day average of 0.783, a z-score of 2.24 that marks the most skewed reading in recent weeks. That is a step up from the 0.84 PCR flagged in the October 8 note, which was itself already elevated. The drift has been steady and deliberate: the PCR was near 0.72 throughout September and has risen in almost every session since. TFC is up 1.1% on the day to $46.64, recovering ground from the month's lows, but that price recovery has not dampened the demand for downside protection. The last two prints reinforce why: July's result produced a 4.2% one-day drop and a further 2.8% over the following week, and April's release also closed lower on the day.
The analyst community has turned more cautious in the week running up to the print. UBS trimmed its target from $55 to $50 while holding Neutral, and JP Morgan cut from $54 to $50.50 while keeping its Underweight rating, both citing margin and loan-growth concerns. TD Cowen reinstated coverage at Hold with a $52 target. The mean consensus target remains $54, implying roughly 16% upside from current levels, but the direction of travel is clear: even the optimists are shaving numbers. Evercore ISI held its Outperform rating but cut to $54, a move that summarises the bull case well: fee income strength, 4.2% commercial loan growth in one segment, a Q2 EPS beat at $1.23, and a raised 2026 fee-growth guide to 10%, but with enough uncertainty to justify trimming. Bears point to anaemic balance-sheet loan growth of just 0.7% quarter-on-quarter annualised against an expected 2.3%, rising nonperforming asset inflows, and the unresolved question of whether the incoming CEO will adjust the 16-18% long-term ROTCE target.
The FDIC call reports tracked by ORTEX Alt Data offer useful colour on the bank's own balance sheet, even though the dataset has not yet accumulated enough history to test as a leading indicator. Net loans and leases at Truist's insured bank charters rose for seven consecutive quarters through April 2026, reaching $327 billion. Total deposits set a record for any Q2 in the available history, coming in at $419 billion. Both readings cover the period ending April 2026, not the quarter this print will report, so they are context rather than signal.
Short interest has continued to fall and is no longer the story. At 2.0% of the free float, it is down 14% on the week, and borrow costs have dropped sharply to 0.276%, less than half their level a week ago. Availability is extremely loose, with roughly 23 shares available to borrow for every one currently lent out. Shorts are not pressing the thesis heading into the release. Capital Research and Management added around 8.8 million shares in the latest reported period to hold 8.6% of the company, making it the largest disclosed institutional holder, and there are no activist positions on the 13D register.
Thursday's print is therefore less a test of whether Truist can grow and more a test of whether management's updated NII and margin guidance, and any early signal from the new CEO on strategic direction, can shift a Street that has spent the past two weeks marking numbers down.
See the live data behind this article on ORTEX.
Open TFC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
